Abbott Laboratories ABT

$108.52 +1.27 (1.18%)

Valuation

Market cap
189,283,936,000
Revenue TTM
$44,328,000,000
Net income TTM
$6,524,000,000
P/E (trailing)
20.53
P/E (forward)
20.03
Profit margin
14.72%
Debt to equity
0.60

Trading

Volume
6,175,556
Avg volume
9,260,490
Day's range
$107.03 – $109.28
Shares out
1,731,942,000
Stochastic %K
8%
Beta
0.54
Analysts
Strong Buy
Price target
$118.96

Price

Company profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic chol...

Show more

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Industry
Medical Devices
Sector
Healthcare
Phone
224 667 6100
Website
https://www.abbott.com
Address
100 Abbott Park Road, Abbott Park, United States

Latest news

Stocktwits

StockTwitsGhost Nov 13, 9:13 PM
$NPCE The selloff prices in execution risk but overlooks the model. At ~$6.30, EV is ~$230M, ~2.5x 2026E sales of $91-92M, for the only FDA-approved closed-loop neurostimulator for epilepsy. Q3 miss traces to likely transitory factors: sales realignment, capacity at a few large centers, SEEG exit. Mgmt says cases were deferred, not lost. Adj. GM 84.8%, adj. EBITDA positive. Trajectory: ~15% core growth in 2027 accelerating toward 20%, before IGE (Breakthrough, mid-‘27) and Remote Care (Q2'27). At ~2.5x sales with 85% margins, a buyout becomes much more plausible. Logical suitors: $MDT (DBS for epilepsy), $LIVN (VNS, epilepsy pure-play), $BSX and $ABT (DBS/neuromod). ~86% institutional, specialist funds hold ~35%. Wouldn’t be surprised to see an approach. Long NPCE.
0 replies
Parlandoconme Nov 13, 8:51 PM
$TOMZ ray ive been working all day and just popped on here. am i quoting you correctly when u said "major drop today" ? $STE $ABT wonder if any BSL-3s or 4s are spraying steramist? bet ray would know since he probably works for bioquell, that shit technology that ruins buildings in the attempt to clean them. Buy baby buy. somebody smart will buyout this company soon and it will rocket to the top. $PFE
0 replies
1212JM Nov 13, 3:31 PM
$ABT $127. EOY target.
0 replies
openclassaction2 Nov 13, 9:30 AM
$ABT a suit alleges freestyle libre 2 sensors gave falsely normal readings, causing dka, per open class actions. lawsuit stage, nothing to claim. seems like a reading is a promise
0 replies
Parlandoconme Nov 12, 7:33 PM
$TOMZ 16-18 cents? ray, that is the lightbulb... Buy now while its high and sell low or better yet get caught holding a second bag. The first one you have is full of all my shares from 2019. Im so pumped you made me rich and now i just watch from a distance as your predictions continue to fail. Thx for all the $$$. I say buy baby buy.Steramist is replacing ll old shit systems and all the BSL's know it. $STE $ABT Anyway, good luck at the earnings call. I got my dough already.
0 replies
Estimize Nov 12, 5:06 PM
Wall St is expecting 1.64 EPS for $ABT Q4 [Reporting 01/27 BMO] http://www.estimize.com/intro/abt?chart=historical&metric_name=eps&utm_cont
0 replies
ST4life Nov 12, 4:18 PM
$ABT $ABBV Abbott should be Abbvie, idiots mixed it up. Dr. Abbott is turning in his grave.
0 replies
scottybebs Nov 12, 4:13 PM
$ABT we were doing great what happend!
1 replies